Search results for: Market Access
Filter search results
Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
17 January 2024
…by delving into five sustainability incentives in the pharmaceutical industry: government regulation, tax incentives, grants and funding, public perception, and market access. He provided examples of where these have been…
Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
4 January 2024
…Dubois et al. note that generic and biosimilar markets in the EU are not efficient, both in the sense of the market share enjoyed by generics and because the end…
Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
1 February 2011
…encourages higher prices in lower-income countries, can delay marketing/patient access in lower-price countries,… This paper examines the potentially positive impact of differential pricing in Europe and the overall negative effects…
New Research: Achieving Efficient Prices for Drugs in a Global Context
7 February 2013
…address this in various ways and will achieve ‘second-best’ dynamic efficiency. Second, insurance coverage distorts markets. Although it contributes to access and protects patients from financial risk, it also can create…
Issues in Development: a Guide
5 January 1983
…like their access to education. Regarding the role of multinational companies in the process of development, the paper argues forcibly that it is a potentially desirable one. In terms of…
Does the New CBO Report Change Anything?
15 September 2021
…in particular our main conclusion that H.R.3. will not curb overall cost growth or make healthcare more affordable or accessible for the average American. Broader reform of the US healthcare…
Around The World in HTAs: Greece – Late but with an Optimistic Future
18 October 2023
…market entry of the tests and patient access to drugs for which a companion diagnostic is a pre-requisite for administration) as well as for patients (regarding access to testing and…
Update: Value-Based Pricing in the UK
11 January 2011
…drugs that reach the market from 1 January 2014. The starting point for price evaluation would be calculation of cost per Quality Adjusted Life Year (QALY). This would assume a…
Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
31 March 2015
…uses of the data for uptake evaluation and research, there should be improved access to data within the appropriate arrangements for governance. Access the full report here. For…